ロード中...
Immune Checkpoint Inhibitors in Non‐Small Cell Lung Cancer
Historically, lung cancer was long considered a poorly immunogenic malignancy. In recent years, however, immune checkpoint inhibitors have emerged as promising therapeutic agents in non‐small cell lung cancer (NSCLC). To date, the best characterized and most therapeutically relevant immune checkpoin...
保存先:
| 出版年: | Oncologist |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Wiley-Blackwell
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5313266/ https://ncbi.nlm.nih.gov/pubmed/27534574 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0189 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|